Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-02-05Clinical Trial Update: Circulating and Molecular Markers Involved in the Processes of Cachexia, Anorexia and Sarcopenia in Patients With NSCLC
This clinical trial investigates circulating and molecular biomarkers involved in cachexia, anorexia, and sarcopenia in patients with non-sm…
-
CLINICAL_TRIALS research · 2025-02-05Clinical Trial Update: The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients [NA]
This clinical trial update explores the potential value of PET/CT in the follow-up care of patients with Stage III non-small cell lung cance…
-
CLINICAL_TRIALS research · 2025-02-05Clinical Trial Update: A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care
This entry describes a prospective clinical trial evaluating plasma genotyping as a noninvasive biomarker to guide genotype-directed cancer …
-
CLINICAL_TRIALS research · 2025-02-04Clinical Trial Update: An Observational Study to Evaluate the Clinical Utility of the Oncomine Precision Assay Within the Exactis Network
This update reports the completion of an observational study evaluating the clinical utility of the Oncomine Precision Assay within the Exac…
-
CLINICAL_TRIALS research · 2025-02-04Clinical Trial Update: Transcriptional Framework for the Molecular Diagnosis of Response to Immunotherapy in Lung Cancer With Agnostic Potential
This clinical trial update describes a transcriptional framework intended to molecularly diagnose response to immunotherapy in non-small cel…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-02-03Clinical Trial Update: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation [Phase 2]
Phase 2 trial evaluating Osimertinib in EGFR-mutant non-small cell lung cancer with brain or leptomeningeal metastases has completed. The st…
-
CLINICAL_TRIALS trial_result · 2025-02-03Clinical Trial Update: Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With Non Small Cell Lung Cancer [Phase 1]
Phase 1 study evaluating safety and immunogenicity of the live-attenuated Listeria immunotherapy JNJ-64041757 in non-small cell lung cancer …
-
CLINICAL_TRIALS trial_result · 2025-02-03Clinical Trial Update: Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers [Phase 1]
Phase 1 study of cosibelimab (CK-301) as a single-agent therapy in adults with advanced cancers; the trial status is active but not recruiti…
-
CLINICAL_TRIALS trial_result · 2025-02-03Clinical Trial Update: --SuPERIOR Trial-- [Phase 2]
Phase 2 clinical trial for Non-Small Cell Lung Cancer was terminated; no results are provided in the update.
-
CLINICAL_TRIALS research · 2025-01-31Clinical Trial Update: Genomic Investigation of Unusual Responders
This clinical trial update describes a University Health Network study investigating genomic factors in unusual responders across multiple c…
-
CLINICAL_TRIALS research · 2025-01-31Clinical Trial Update: Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) [Phase 1, Phase 2]
Phase 1/2 MORNINGSTAR trial evaluating mavrostobart (PT199), an anti-CD73 antibody, alone or with a PD-1 inhibitor or chemotherapy in non-sm…
-
CLINICAL_TRIALS trial_result · 2025-01-31Clinical Trial Update: HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy [Phase 3]
Phase 3 trial comparing patritumab deruxtecan to platinum-based chemotherapy in EGFR-mutant non-small cell lung cancer after EGFR TKI failur…
-
CLINICAL_TRIALS trial_result · 2025-01-30Clinical Trial Update: Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation [Phase 3]
A Phase 3 trial comparing Capmatinib to Docetaxel in previously treated non-small cell lung cancer with MET exon 14 skipping mutation was te…
-
CLINICAL_TRIALS research · 2025-01-30Clinical Trial Update: Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) [Phase 2]
Phase 2 platform clinical trial ORCHARD investigates treatment options for advanced non-small cell lung cancer in patients who progressed on…
-
CLINICAL_TRIALS research · 2025-01-30Clinical Trial Update: Digital Lifestyle Intervention for Lung Cancer Survivors [NA]
An ongoing clinical study is evaluating a digital lifestyle intervention for survivors of non-small cell lung cancer and is currently recrui…
-
CLINICAL_TRIALS trial_result · 2025-01-30Clinical Trial Update: IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study [Phase 2]
Phase II IMMUNOSABR trial testing immunotherapy with stereotactic ablative radiotherapy for stage IV non-small cell lung cancer was terminat…
-
CLINICAL_TRIALS trial_result · 2025-01-29Clinical Trial Update: The Effect of Nurse Navigation Program on Lung Cancer Patients [NA]
This entry reports the completed clinical trial from Akdeniz University evaluating the effect of a nurse navigation program on patients with…
-
CLINICAL_TRIALS trial_result · 2025-01-29Clinical Trial Update: A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer
This completed clinical trial assessed the prevalence of overexpression of a specific protein in adults with non-small cell lung cancer. The…
-
CLINICAL_TRIALS trial_result · 2025-01-29Clinical Trial Update: Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28) [Phase 3]
Phase 3 trial comparing durvalumab with low-dose prophylactic cranial irradiation (PCI) versus durvalumab with observation in radically trea…
-
CLINICAL_TRIALS research · 2025-01-29Clinical Trial Update: A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study of the bispecific antibody MCLA-158 in patients with advanced solid tumors. Recruitme…
-
EMA approval · 2025-01-28EMA Authorised: Augtyro (repotrectinib) — Bristol-Myers Squibb Pharma EEIG
EMA authorised Augtyro (repotrectinib) for non-small cell lung cancer under a conditional marketing authorization. The marketing authorizati…
-
CLINICAL_TRIALS trial_result · 2025-01-28Clinical Trial Update: Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M [Phase 2]
This Phase 2 trial evaluated osimertinib as first-line therapy in locally advanced or metastatic non-small cell lung cancer patients with EG…
-
CLINICAL_TRIALS trial_result · 2025-01-28Clinical Trial Update: A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) [Phase 1]
Phase 1 study of mRNA-5671/V941 as monotherapy and in combination with pembrolizumab (V941-001) was terminated, with results posted on 2025-…
-
CLINICAL_TRIALS research · 2025-01-28Clinical Trial Update: Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL) [Phase 2]
Phase 2 clinical trial evaluating a pragmatic adoptive cell therapy approach using an IL2 analog (ANV419) versus high-dose IL-2 after tumor-…
-
CLINICAL_TRIALS trial_result · 2025-01-27Clinical Trial Update: Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer [Phase 2]
A Phase 2 clinical trial update reports results for pembrolizumab with or without standard chemotherapy in adults aged 70 and older with adv…